Trials / Terminated
TerminatedNCT02113397
Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung
Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI™ Podhaler™) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI™ Podhaler™) and Inhaled Colistimethate
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Dartmouth-Hitchcock Medical Center · Academic / Other
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize bacterial diversity and richness in the sputum of cystic fibrosis patients treated with every-other-month TOBI™ Podhaler™ and continuous alternating therapy with TOBI™ Podhaler and colistimethate (Colistin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TOBI™ Podhaler™ 112 mg inhaled twice daily | |
| DRUG | Colistimethate 75 mg inhaled two times daily |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2014-04-14
- Last updated
- 2018-03-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02113397. Inclusion in this directory is not an endorsement.